Perrigo Company (Nasdaq: PRGO;TASE) announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug application (ANDA) for Desloratadine tablets (5 mg). Perrigo had been sued for patent infringement based upon its filing of an ANDA containing a Paragraph IV certification and settled the case in 2008…
Allergy News From Medical News Today Tags: announces, Approval, Desloratadine, final, Perrigo
This entry was posted on December 29, 2011 at 10:18 am and is filed under Allergy. You can follow any responses to this entry through the RSS 2.0 feed.
